TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Bausch + Lomb Corporation ( (BLCO) ) is now available.
Bausch + Lomb reported a revenue of $1.137 billion for the first quarter of 2025, marking a 3% increase from the previous year. Despite a GAAP net loss of $212 million, the company showed growth in its Vision Care and Surgical segments, driven by increased sales in contact lenses and surgical equipment. The company is updating its full-year guidance due to the enVista intraocular lenses recall and foreign exchange impacts. Bausch + Lomb remains committed to long-term growth and enhancing eye health standards, with ongoing advancements in its product offerings.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
Bausch + Lomb’s financial performance is mixed, with strong revenue growth but challenges in profitability and increased leverage. The technical analysis shows a bearish trend, and valuation metrics are weak due to net losses. However, the company’s positive earnings call guidance and strategic focus on innovation provide a more optimistic outlook, balancing some of the financial and technical challenges.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb Corporation is a leading global eye health company focused on improving vision and eye care. The company offers a range of products including contact lenses, intraocular lenses, and pharmaceuticals, with a strong emphasis on consumer growth and advancing its product pipeline.
YTD Price Performance: -24.11%
Average Trading Volume: 734,096
Technical Sentiment Signal: Buy
Current Market Cap: $4.83B
Learn more about BLCO stock on TipRanks’ Stock Analysis page.